Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov’s model-based evaluation
Frontiers in Public Health · 2025
DOI: 10.3389/fpubh.2025.1574780 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, 2025. Verfasst von Juan Hong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of M…. Hauptthemen laut MEDLINE: Tosyl Compounds, Anilides, Nitriles, Prostatic Neoplasms. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Rezvilutamide, an androgen-receptor inhibitor, has been approved by the Chinese National Medical Products Administration as a first-line treatment for high-volume metastatic hormone-sensitive prostate cancer (mHSPC). This study aims to assess the cost-effectiveness of rezvilutamide plus androgen-deprivation therapy (ADT) compared to bicalutamide plus ADT for the first-line treatment of high-volume mHSPC in China.
Methods
A Markov model with three health states was developed to evaluate the health and economic outcomes of first-line treatment for high-volume mHSPC. Efficacy data were sourced from the CHART trial. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) were calculated. To address modeling uncertainties, one-way sensitivity analysis and probabilistic sensitivity analysis were performed.
Results
Compared with bicalutamide plus ADT, rezvilutamide plus ADT resulted in an additional 2.16 QALYs, with an ICER of $39,122.16/QALY. At a willingness-to-pay (WTP) threshold of three times the gross domestic product per capita in China for 2023 ($37,256.3/QALY), the probability of cost-effectiveness for rezvilutamide plus ADT was 30%. One-way sensitivity analysis revealed that the results were most sensitive to the cost of rezvilutamide. Scenario analysis indicated that rezvilutamide could be considered cost-effective if priced below $705.46 per cycle.
Conclusion
From the perspective of Chinese payers, rezvilutamide plus ADT appears to be a less cost-effective strategy compared to bicalutamide plus ADT for the first-line treatment of high-volume mHSPC in China.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
- Department of Nuclear Medicine/PET Image Center, The Second Xiangya Hospital of Central South University, Changsha, China.
- School of Pharmacy, Guangdong Medical University, Dongguan, China.
- Department of Pharmacy, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Zitieren
APA
Hong, J., Zeng, X., Chen, W., Zhou, Z., He, Y., Meng, J., & Ouyang, L. (2025). Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov’s model-based evaluation. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2025.1574780
Vancouver
Hong J, Zeng X, Chen W, Zhou Z, He Y, Meng J, et al. Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov’s model-based evaluation. Frontiers in Public Health. 2025. doi:10.3389/fpubh.2025.1574780
BibTeX
@article{Hong2025,
author = {Hong, Juan and Zeng, Xiaohui and Chen, Wenjun and Zhou, Ziyuan and He, Yuming and Meng, Jun and Ouyang, Lihui},
title = {Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov’s model-based evaluation},
journal = {Frontiers in Public Health},
year = {2025},
doi = {10.3389/fpubh.2025.1574780}
}
EUVIMED